NCT01333878View on ClinicalTrials.gov

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

January 31, 2014

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Subcutaneous Abatacept

Subcutaneous Abatacept 125 mg once weekly for 6 months

Trial Locations (1)

90404

Orrin M. Troum, MD and Medical Associates, Santa Monica

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Orrin M Troum, M.D. and Medical Associates

OTHER

NCT01333878 - Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage | Biotech Hunter | Biotech Hunter